FDA Approves the First Eye-Specific Bevacizumab for Wet Macular Degeneration After Two Decades of Off-Label Use

FDA approved Lytenava, the first ophthalmic bevacizumab for wet AMD. What it changes for patients who already get compounded Avastin.

Have A Referral?